Vista Partners Initiates Coverage on Opexa Therapeutics, Inc.; Target Price $4.40

LOS ANGELES, Sept. 13 /PRNewswire/ -- Vista Partners announced today that it has initiated coverage on Opexa Therapeutics, Inc. (Nasdaq: OPXA) with a twelve month target price of $4.40. Ross Silver, Principal Analyst at Vista Partners stated, "Opexa's lead clinical candidate Tovaxin®, an autologous cellular immunotherapy for the treatment of Multiple sclerosis, has shown promising clinical data to date.  In addition, the company's stem cell therapy is partnered with Novartis. Dendreon's Provenge®, the first FDA-approved autologous cellular immunotherapy, has increased awareness and acceptance for this therapeutic approach and likely increased Opexa's value amongst potential partners."  

To download a FREE copy of the Opexa Therapeutics, Inc. research report, please visit and complete the research form to gain access to the report.  

About Vista Partners:

With offices in California and Oregon, Vista Partners LLC is one of the fastest growing independently owned research and consulting firms in the United States. Vista Partners professional staff has backgrounds in finance, corporate communications and investment banking.


Phone: 877.215.4813

Email: [email protected]

SOURCE Vista Partners

Launch Readiness

Optimize cross-functional collaboration and engage with key stakeholders for the successful launch of a product

Join the Launch Readiness for Medical Affairs & Communications Teams Summit to learn best practices in taking a structured approach to enhance medical affairs activities surrounding a launch and increase knowledge and communication with thought leaders.